B. Braun's Multi-Loc Multiple Stent Delivery System Evaluated to Treat Femoropopliteal Lesions


September 6, 2017—A report of 6-month outcomes from the first clinical experience with the Multi-Loc multiple stent delivery system (B. Braun Melsungen AG) for focal stenting in long femoropopliteal lesions was published by Klaus Amendt, MD, et al online in Vasa: European Journal of Vascular Medicine.

As summarized in Vasa, the primary endpoint of the observational, multicenter LOCOMOTIVE study was the rate of target lesion revascularization (TLR) at 6 months. In the study, femoropopliteal lesions were prepared with uncoated and/or paclitaxel-coated peripheral balloon catheters. When flow-limiting dissections, elastic recoil, or recoil caused by calcification required stenting, investigators implanted up to six short stents per delivery device, each 13 mm in length. Sonographic follow-ups and clinical assessments were scheduled at 6 months.

The investigators reported that a total of 75 patients aged 72.9 ± 9.2 years were enrolled. Of the 176 individually treated lesions,134 (76.2%) were in the superficial femoral artery; the rate of TASC C/D lesions was 51.1% (90/176). The total lesion length was 14.5 ± 9.0 cm, with a reference vessel diameter of 5.6 ± 0.7 mm. Overall, 47% ± 18% of lesion lengths could be saved from stenting.

At 6 months, the patency rate was 90.7% (68/75) and the all-cause TLR rate was 5.3% (4/75) in the overall cohort.

The first clinical experience at 6 months suggests that treatment with the Multi-Loc multiple stent delivery system was safe and effective to treat femoropopliteal lesions of considerable length (14.5 ± 9.0 cm). Almost half of the lesion length could be saved from stenting, patency was high, and TLR rates were acceptably low, concluded the LOCOMOTIVE investigators in Vasa.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.